Last reviewed · How we verify

UCB Pharma — Portfolio Competitive Intelligence Brief

UCB Pharma pipeline: 11 marketed, 0 filed, 13 Phase 3, 5 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

11 marketed 0 filed 13 Phase 3 5 Phase 2 8 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Niravam Niravam marketed Other
Levetiracetam (Keppra) Levetiracetam (Keppra) marketed Antiepileptic drug (AED) SV2A (synaptic vesicle protein 2A) Neurology
Certolizumab Pegol (CZP) Certolizumab Pegol (CZP) marketed TNF-alpha inhibitor TNF-alpha Immunology
Methylphenidate Extended Release Capsules Methylphenidate Extended Release Capsules marketed Sympathomimetic amine; central nervous system stimulant Dopamine transporter (DAT); Norepinephrine transporter (NET) Neurology; Psychiatry
Levocetirizine (drug) Levocetirizine (drug) marketed H1-receptor antagonist (second-generation antihistamine) H1-receptor Allergy/Immunology
Levocetirizine oral solution Levocetirizine oral solution marketed H1-receptor antagonist (second-generation antihistamine) H1 receptor Allergy/Immunology
Cetirizine drops Cetirizine drops marketed H1-receptor antagonist (second-generation antihistamine) H1 receptor Immunology / Allergy
Cetirizine tablets Cetirizine tablets marketed H1-receptor antagonist (second-generation antihistamine) H1 receptor Immunology / Allergy
SSRI/SNRI SSRI/SNRI marketed SSRI/SNRI Serotonin transporter (SERT); norepinephrine transporter (NET) for SNRIs Psychiatry/Neurology
Kemstro Kemstro marketed Other
Neupro® Neupro® marketed Dopamine agonist Dopamine receptors (D1, D2, D3, D4, D5) Neurology
Placebo-Levocetirizine Placebo-Levocetirizine phase 3 H1-receptor antagonist (second-generation antihistamine) H1 receptor Allergy/Immunology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. GlaxoSmithKline · 4 shared drug classes
  2. Pfizer · 3 shared drug classes
  3. Oregon Health and Science University · 2 shared drug classes
  4. Eisai Inc. · 2 shared drug classes
  5. Massachusetts General Hospital · 2 shared drug classes
  6. Merck Sharp & Dohme LLC · 2 shared drug classes
  7. · 2 shared drug classes
  8. AstraZeneca · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for UCB Pharma:

Cite this brief

Drug Landscape (2026). UCB Pharma — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/ucb-pharma. Accessed 2026-05-13.

Related